Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the efficacy of TCM as an effective supplement in addition to the traditional treatment in RA.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong

Criteria

Inclusion Criteria:

• Fulfilled the 1987 American College of Rheumatology (ACR) criteria for RA.

• The presence of 2 or more swollen or tender joints, based on 28-joint count.

• Morning stiffness lasting for 30 minutes.

• Erythrocyte sedimentation rate (ESR) of 28 mm/hour, despite treatment with disease modifying agent including MTX, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study.

• Patients taking glucocorticoids (prednisone < 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial.

• Patients had radiographic erosive diseases.

Exclusion Criteria:

• Patients who are pregnant or nursing mothers.

• Severe liver disease (e.g cirrhosis, chronic active hepatitis)

• Renal impairment (serum creatinine level > 150mmol/L)

• Known hypersensitivity to herbal medicine